|
Orthologous residues
|
|
Smad3 (human): T179‑p, Smad3 (mouse): T179‑p, Smad3 (rat): T179‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
293T (epithelial), HaCaT (keratinocyte)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
EGF
|
|
|
|
increase
|
|
|
TGF-beta
|
|
|
|
increase
|
|
|
SB431542
|
TGF-beta
|
|
|
inhibit treatment-induced increase
|
|
|
flavopiridol
|
TGF-beta
|
|
|
inhibit treatment-induced increase
|
|
|
U0126
|
TGF-beta
|
|
|
no effect upon treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
NEDD4L (human)
|
|
Induces
|
|
|
co-immunoprecipitation
|
|